{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:39:42Z","timestamp":1788932382832,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,18]]},"DOI":"10.7759\/cureus.82532","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T18:59:06Z","timestamp":1745002746000},"source":"Crossref","is-referenced-by-count":3,"title":["Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials"],"prefix":"10.7759","author":[{"given":"Ciara","family":"Mimms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassandra","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Saboor","family":"Khaliq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre RS","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, et al.. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023, 22:394-412. 10.1002\/wps.21120","journal-title":"World Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos D","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020, 16:221-34. 10.2147\/NDT.S198774","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12703\/r\/12-13","article-title":"Recent advances in electroconvulsive therapy in clinical practice and research","volume":"12","author":"Mukhtar F","year":"2023","unstructured":"Mukhtar F, Regenold W, Lisanby SH. Recent advances in electroconvulsive therapy in clinical practice and research. Fac Rev. 2023, 12:13. 10.12703\/r\/12-13","journal-title":"Fac Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.727117","article-title":"Psychedelics and other psychoplastogens for treating mental illness","volume":"12","author":"Vargas MV","year":"2021","unstructured":"Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and other psychoplastogens for treating mental illness. Front Psychiatry. 2021, 12:727117. 10.3389\/fpsyt.2021.727117","journal-title":"Front Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero P","year":"2018","unstructured":"Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-S\u00e1nchez E, Guti\u00e9rrez-Rojas L, Meana JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs. 2018, 32:411-20. 10.1007\/s40263-018-0519-3","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-013-9230-9","article-title":"Efficacy of cognitive rehabilitation therapies for mild cognitive impairment (MCI) in older adults: working toward a theoretical model and evidence-based interventions","volume":"23","author":"Huckans M","year":"2013","unstructured":"Huckans M, Hutson L, Twamley E, Jak A, Kaye J, Storzbach D. Efficacy of cognitive rehabilitation therapies for mild cognitive impairment (MCI) in older adults: working toward a theoretical model and evidence-based interventions. Neuropsychol Rev. 2013, 23:63-80. 10.1007\/s11065-013-9230-9","journal-title":"Neuropsychol Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","unstructured":"Depression assessment instruments. (2023). Accessed. April 16, 2025: https:\/\/www.apa.org\/depression-guideline\/assessment."},{"key":"ref10","unstructured":"RoB 2. a revised Cochrane risk-of-bias tool for randomized trials. (2025). Accessed: April 16, 2025: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03063-x","article-title":"Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial","volume":"30","author":"Glue P","year":"2024","unstructured":"Glue P, Loo C, Fam J, et al.. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024, 30:2004-9. 10.1038\/s41591-024-03063-x","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17786","article-title":"Ketamine vs electroconvulsive therapy for treatment-resistant depression: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jha MK","year":"2024","unstructured":"Jha MK, Wilkinson ST, Krishnan K, et al.. Ketamine vs electroconvulsive therapy for treatment-resistant depression: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024, 7:e2417786. 10.1001\/jamanetworkopen.2024.17786","journal-title":"JAMA Netw Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02468-x","article-title":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial","volume":"29","author":"Papakostas GI","year":"2024","unstructured":"Papakostas GI, Trivedi MH, Shelton RC, et al.. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024, 29:2287-95. 10.1038\/s41380-024-02468-x","journal-title":"Mol Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.12.061","article-title":"The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression","volume":"372","author":"Goodwin GM","year":"2025","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al.. The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. J Affect Disord. 2025, 372:523-32. 10.1016\/j.jad.2024.12.061","journal-title":"J Affect Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"29","author":"Smith-Apeldoorn SY","year":"2024","unstructured":"Smith-Apeldoorn SY, Veraart JK, Kamphuis J, et al.. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. Mol Psychiatry. 2024, 29:2657-65. 10.1038\/s41380-024-02478-9","journal-title":"Mol Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.02.052","article-title":"Cognitive outcomes from the randomised, active-controlled ketamine for adult depression study (KADS)","volume":"352","author":"Martin DM","year":"2024","unstructured":"Martin DM, Harvey AJ, Baune B, et al.. Cognitive outcomes from the randomised, active-controlled ketamine for adult depression study (KADS). J Affect Disord. 2024, 352:163-70. 10.1016\/j.jad.2024.02.052","journal-title":"J Affect Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae046","article-title":"Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from four phase 3 studies","volume":"27","author":"Morrison RL","year":"2024","unstructured":"Morrison RL, Singh J, Daly E, et al.. Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from four phase 3 studies. Int J Neuropsychopharmacol. 2024, 27:pyae046. 10.1093\/ijnp\/pyae046","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.12.013","article-title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: findings from a 32-week randomised, open-label, rater-blinded phase IIIb study","volume":"93","author":"Vieta E","year":"2025","unstructured":"Vieta E, Ahmed N, Arango C, et al.. Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. Eur Neuropsychopharmacol. 2025, 93:29-39. 10.1016\/j.euroneuro.2024.12.013","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15449","article-title":"Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder","volume":"86","author":"Goodwin GM","year":"2025","unstructured":"Goodwin GM, Nowakowska A, Atli M, et al.. Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder. J Clin Psychiatry. 2025, 86:24m15449. 10.4088\/JCP.24m15449","journal-title":"J Clin Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2024.104171","article-title":"A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression","volume":"99","author":"Kumar PS","year":"2024","unstructured":"Kumar PS, Menon V, Andrade C. A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression. Asian J Psychiatr. 2024, 99:104171. 10.1016\/j.ajp.2024.104171","journal-title":"Asian J Psychiatr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/bs13040297","article-title":"Psychotherapy with psilocybin for depression: systematic review","volume":"13","author":"Dawood Hristova JJ","year":"2023","unstructured":"Dawood Hristova JJ, P\u00e9rez-Jover V. Psychotherapy with psilocybin for depression: systematic review. Behav Sci (Basel). 2023, 13:297. 10.3390\/bs13040297","journal-title":"Behav Sci (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911450","article-title":"Esketamine and psilocybin\u2014the comparison of two mind-altering agents in depression treatment: systematic review","volume":"23","author":"Psiuk D","year":"2022","unstructured":"Psiuk D, Nowak EM, Dycha N, \u0141opusza\u0144ska U, Kurzepa J, Samardakiewicz M. Esketamine and psilocybin\u2014the comparison of two mind-altering agents in depression treatment: systematic review. Int J Mol Sci. 2022, 23:11450. 10.3390\/ijms231911450","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1459633","article-title":"Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study","volume":"15","author":"Oliveira-Maia AJ","year":"2024","unstructured":"Oliveira-Maia AJ, Rive B, Godinov Y, Mulhern-Haughey S. Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study. Front Psychiatry. 2024, 15:1459633. 10.3389\/fpsyt.2024.1459633","journal-title":"Front Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13741","article-title":"Impact of psilocybin on cognitive function: a systematic review","volume":"78","author":"Meshkat S","year":"2024","unstructured":"Meshkat S, Tello-Gerez TJ, Gholaminezhad F, et al.. Impact of psilocybin on cognitive function: a systematic review. Psychiatry Clin Neurosci. 2024, 78:744-64. 10.1111\/pcn.13741","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126713","article-title":"Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior","volume":"23","author":"Wojtas A","year":"2022","unstructured":"Wojtas A, Bysiek A, Wawrzczak-Bargiela A, et al.. Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior. Int J Mol Sci. 2022, 23:6713. 10.3390\/ijms23126713","journal-title":"Int J Mol Sci"},{"key":"ref26","unstructured":"Sheehan disability scale. (2025). Accessed. April 16, 2025: https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/sheehan-disability-scale."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359977-comparative-efficacy-and-functional-outcomes-of-psychedelic-assisted-therapies-in-treatment-resistant-depression-a-systematic-review-of-recent-clinical-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T18:59:08Z","timestamp":1745002748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359977-comparative-efficacy-and-functional-outcomes-of-psychedelic-assisted-therapies-in-treatment-resistant-depression-a-systematic-review-of-recent-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.82532","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}